Supplementary Table S2. Multivariate analysis of impact factors for ypN+ in breast non-pathological complete remission (pCR) patients

Factors	OR	95% CI	P-value
Clinical stage			**<0.001**
cT1-2N0	1		
cT1-2N1	5.51	3.71-8.16	**<0.001**
LABC	10.63	6.76-16.72	**<0.001**
ER			0.131
Negative	1		
Positive	1.31	0.92-1.86	
PR			0.515
Negative	1		
Positive	0.85	0.52-1.39	
HER2			0.353
Negative	1		
Positive	0.83	0.56-1.42	
Molecular subtypes			0.634
Luminal A-like	1		
Luminal B (HER2-)	1.19	0.62-2.30	0.599
Luminal B (HER2+)	0.85	0.41-1.73	0.650
HER2-amplified	1.43	0.33-6.27	0.638
TNBC	1.31	0.30-5.74	0.718
Grade			0.065
I-II	1		
III	1.38	0.98-1.23	
NAC regimens			0.090
Containing A	1		
Containing T	0.67	0.35-1.28	0.221
A+T combination	1.13	0.68-1.87	0.641
Neoadjuvant targeted therapy			**0.001**
Yes	1		
No	2.15	1.39-3.32	

Abbreviations: OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; NAC, neoadjuvant chemotherapy; A, anthracyclines; T, taxanes; pCR, pathological complete remission.